Kura Oncology CMO Stephen Dale resigns; Mollie Leoni named CMO, Francis Burrows CSO

Kura Oncology, Inc.

Stephen Dale, M.D. resigned as CMO effective Jan 2, 2025 due to personal health challenges.
Settlement provides 18 months base salary, 2024 bonus, and extended option exercise through Mar 31, 2026.
Mollie Leoni, M.D. appointed Chief Medical Officer on Jan 2, 2025.
Francis Burrows, Ph.D. appointed Chief Scientific Officer on Jan 2, 2025.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stephen Dale

Chief Medical Officer

KURA · Kura Oncology, Inc.

Effective: 2025-01-02
Filed: January 6, 2025, 6:59 PM ET

On January 1, 2025 (the “Dale Separation Date”), Stephen Dale, M.D. tendered his resignation from his position as the Chief Medical Officer of Kura Oncology, Inc. (the “Company”), effective as of January 2, 2025, in order to focus on recovery from personal health challenges.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Dale resigned as Chief Medical Officer at Kura Oncology, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On January 1, 2025 (the “Dale Separation Date”), Stephen Dale, M.D. tendered his resignation from his position as the Chief Medical Officer of Kura Oncology, Inc. (the “Company”), effective as of January 2, 2025, in order to focus on recovery from personal health challenges.

View on SEC.gov

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-002189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.